<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04465630</url>
  </required_header>
  <id_info>
    <org_study_id>06807</org_study_id>
    <nct_id>NCT04465630</nct_id>
  </id_info>
  <brief_title>A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma</brief_title>
  <acronym>ORION</acronym>
  <official_title>A Prospective, Multicenter Study of the OMNI® Surgical System in Pseudophakic Eyes With Open Angle Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sight Sciences, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sight Sciences, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To prospectively assess the clinical effect of ab-interno transluminal viscoelastic delivery&#xD;
      and trabeculotomy performed with the OMNI Surgical System in pseudophakic eyes on intraocular&#xD;
      pressure (IOP) and the use of IOP-lowering medications in patients with open angle glaucoma&#xD;
      (OAG).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Sponsor Decision&#xD;
  </why_stopped>
  <start_date type="Actual">June 19, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Decrease in intraocular pressure (IOP)</measure>
    <time_frame>12 months</time_frame>
    <description>Decrease in unmedicated mean diurnal IOP (DIOP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Decrease in number of medications</measure>
    <time_frame>12 months</time_frame>
    <description>Change in the number of ocular hypotensive medications at the between screening and 12-month postoperative visit.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Glaucoma, Open-Angle</condition>
  <arm_group>
    <arm_group_label>Pseudophakic eyes with Open Angle Glaucoma</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Eligible subjects enrolled in the trial will receive surgery for Open Angle Glaucoma using the OMNI® Surgical System.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OMNI® Surgical System</intervention_name>
    <description>Ab-interno transluminal viscoelastic delivery and trabeculotomy performed with the OMNI Surgical System</description>
    <arm_group_label>Pseudophakic eyes with Open Angle Glaucoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female subjects, 22 years or older at the time of surgery&#xD;
&#xD;
          -  History of uncomplicated cataract surgery and posterior chamber IOL implantation&#xD;
             without compromise to the lens capsule, zonular dehiscence/rupture or vitreous&#xD;
             prolapse, 6 months or more prior to Baseline Visit.&#xD;
&#xD;
          -  Diagnosed with mild to moderate open angle glaucoma (e.g. primary open angle glaucoma,&#xD;
             pigmentary glaucoma, pseudoexfoliative glaucoma) as documented in subjects' medical&#xD;
             record substantiated using funduscopic exam or OCT and at least one visual field test&#xD;
             with the Humphrey automated perimeter using the SITA Standard 24-2 testing algorithm.&#xD;
&#xD;
               -  Mean deviation score must be better than or equal to -12.0 dB&#xD;
&#xD;
               -  The visual field test may be historical (within 6 months prior to Screening&#xD;
                  Visit). If needed, visual field testing may be repeated between the Screening&#xD;
                  Visit and the Surgery Visit.&#xD;
&#xD;
          -  At the Screening visit, IOP of ≤ 36 mmHg while on 1-5 ocular hypotensive medications1&#xD;
             with a stable medication regimen for at least 2 months.&#xD;
&#xD;
          -  At Baseline visit, unmedicated diurnal i) IOP ≥ 22.5 and ≤ 39mmHg and ii) IOP at least&#xD;
             3 mmHg higher than screening IOP and iii) IOP at 7:30AM ≥ 24&#xD;
&#xD;
          -  Scheduled for ab-interno transluminal viscoelastic delivery and trabeculotomy using&#xD;
             the OMNI Surgical System.&#xD;
&#xD;
          -  Shaffer grade of ≥ III in all four quadrants&#xD;
&#xD;
          -  Able and willing to comply with the protocol, including all follow-up visits.&#xD;
&#xD;
          -  Understands and signs the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any of the following prior treatments for glaucoma:&#xD;
&#xD;
               -  Laser trabeculoplasty ≤3 months prior to Baseline visit&#xD;
&#xD;
               -  iStent or iStent Inject implanted ≤6 months prior to Baseline visit&#xD;
&#xD;
               -  Endocyclophotocoagulation (ECP) or Micropulse laser ≤ 6 months prior to Baseline&#xD;
                  visit&#xD;
&#xD;
               -  Trabeculectomy or other bleb forming procedure including Xen, Express, glaucoma&#xD;
                  draining device/valve&#xD;
&#xD;
               -  Prior canaloplasty, goniotomy, or trabeculotomy&#xD;
&#xD;
               -  Hydrus microstent&#xD;
&#xD;
               -  Suprachoroidal stent (e.g. Cypass, iStent Supra)&#xD;
&#xD;
          -  Acute angle closure, traumatic, congenital, malignant, uveitic or neovascular glaucoma&#xD;
&#xD;
          -  Concurrent IOP-lowering procedure other than use of the OMNI Surgical System at the&#xD;
             time of surgery (e.g. ECP, CPC, etc.)&#xD;
&#xD;
          -  In the Investigator's judgement, predisposed to significant risk because of washout of&#xD;
             ocular hypotensive medications&#xD;
&#xD;
          -  Concurrent ocular pathology or systemic medical condition which, in the Investigator's&#xD;
             judgment, would either place the subject at increased risk of complications,&#xD;
             contraindicate surgery, place the subject at risk of significant vision loss during&#xD;
             the study period (e.g., wet AMD, corneal edema, Fuch's dystrophy, active intraocular&#xD;
             infection or inflammation within 30 days prior to Screening Visit, etc.), or interfere&#xD;
             with compliance to elements of the study protocol (e.g., returning to Investigator's&#xD;
             office for follow-up visits).&#xD;
&#xD;
          -  History of penetrating keratoplasty or another corneal transplant&#xD;
&#xD;
          -  BCVA of logMAR 1.0 (20/200) or worse in the fellow eye not due to cataract&#xD;
&#xD;
          -  Study of OMNI System in POAG&#xD;
&#xD;
          -  BCVA of logMAR 0.4 (20/50) or worse in the study eye not due to posterior capsular&#xD;
             opacification (uneventful Nd:YAG laser capsulotomy 6 months prior to baseline is&#xD;
             permitted only if there is no vitreous present in or in front of the iris plane at the&#xD;
             time of baseline).&#xD;
&#xD;
          -  Participation (≤ 30 days prior to baseline) in an interventional trial which could&#xD;
             have a potential effect on the study outcome, as determined by the study investigator&#xD;
&#xD;
          -  Women of childbearing potential if they are currently pregnant or intend to become&#xD;
             pregnant during the study period; are breast-feeding; or are not in agreement to use&#xD;
             adequate birth control methods to prevent pregnancy throughout the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vold Vision</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bay Eye Associates</name>
      <address>
        <city>Petaluma</city>
        <state>California</state>
        <zip>94954</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assil Eye Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grene Vision Group</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>62708</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Eye Consultants</name>
      <address>
        <city>Bloomington</city>
        <state>Minnesota</state>
        <zip>55431</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Eye Surgeons</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Eye Specialists</name>
      <address>
        <city>Maryville</city>
        <state>Tennessee</state>
        <zip>37803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>El Paso Eye Surgeons</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ophthalmology Associates - Fort Worth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Utah Eye Centers</name>
      <address>
        <city>Ogden</city>
        <state>Utah</state>
        <zip>84403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>July 7, 2020</study_first_submitted>
  <study_first_submitted_qc>July 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 10, 2020</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
    <mesh_term>Glaucoma, Open-Angle</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

